-
Blood: IL10RA regulates the sensitivity of NPM1-ALK plus interstituated large cell lymphoma to keratosini
Time of Update: 2020-07-12
Interstituatorcell lymphoma (alCL), also known as ki-1 lymphoma, is a T-cell malignant tumor that is mainly driven by an overactive interstitliated lymphoma kinase (ALK) fusion protein ALK inhibit
-
Blood: A new red blood cell production regulation mode
Time of Update: 2020-07-12
Eryteonin (Epo) provides the primary survival signal for mature erythropoietin (EPs) and is essential for end-of-life erythropoietin production Still, progenitor cells can irreversibly differentiate
-
Nature: What are the different rates of blood cancer in different populations?
Time of Update: 2020-07-12
At present, it is not clear to what extent the biology of tumor occurrence and aging is shaped by differences in human populations As you age, hematopoietic cloning with acquired mutations becomes c
-
Blood: Promoting red blood cell production joint iron restriction seislus significantly improved anemia of beta-thalassemia
Time of Update: 2020-07-12
Moderate thalassemia is a disease characterized by red blood cell production ineffective (IE), anemia, spleen enlargement, and systemic iron overload Researchers are exploring new treatments based o
-
Blood: Lysine-specific demethylatase 1A (LSD1) limits in vitro amplification of human HSC and is a target for UM171
Time of Update: 2020-07-12
At present, hematopoietic stem cells transplantation is still the only cure for a variety of malignant blood diseases, but has been limited by the lack of cell donors, high-quality cells can not f
-
Collection: Blood Research Selected on June 25, 2020
Time of Update: 2020-07-12
1 The primary cell-like chronic myeloid leukemia model based on genetic heterogeneity BCR-ABL1 kinase targeted therapy revolutionized the treatment of chronic stage (CP) chronic myeloid leukemia
-
Once a week, subcutaneous injection of C5 supplement inhibitor ULTOMIRIS, treatment of burst sleep-based hemoglobinuria reached the clinical endpoint of Stage III
Time of Update: 2020-07-12
Alexion Pharmaceuticals announced that its weekly patient self-inderite injection ULTOMIRIS treatment of bisonal hemoglobinuria (PNH) has reached the primary end of the trial On the 71st day, subcut
-
Brit J Heamatol: Clinical Outcome of T-Cell Large Particle Lymphocytic Leukemia
Time of Update: 2020-07-12
T-cell large granulele leukemia (T-LGLL) is an incurable form of leukemia characterized by abnormal cytotoxic T-cell cloning proliferation, which can lead to severe neutrophil reduction, blood trans
-
WFH 2020: Four-year data show that type A haemophilia gene therapy valoctocogene roxaparvovec can continue to reduce bleeding
Time of Update: 2020-07-12
BioMarin, a pharmaceutical company, recently released the results of an ongoing Phase I/II trial, which for four years showed a significant reduction in bleeding rates and improved levels of factor
-
Blood: The molecular mechanism of RUNX1 methylation disorder induced leukemia
Time of Update: 2020-07-12
RUNX1 is the most common mutant gene in human leukemia, and loss or dominant negative inhibition of RUNX1 function is found in myelogenic hyperplasia syndrome and acute myeloid leukemia (AML) Howeve
-
Blood: The new alternative to the ditric ludes, acute grafts for host disease!
Time of Update: 2020-07-12
Acute Transplant Anti-Host Disease (GVHD) is a life-threatening complication of allo-HCT The current GVHD treatment is primarily a immune system that targets the donor, and a recent study in the j
-
Brit J Heamatol: Serum BDNF concentration seisprediction of multiple neuropathy and total survival in patients with multiple myeloma
Time of Update: 2020-07-12
Brain-derived neurotrophic factor (BDNF) is a protein that has multiple effects on neurons and vascular function However, its prognosis and function in multiple myeloma (MM) are still unknown , r
-
AACR 2020: Oral PD-L1 inhibitor CCX559, anti-tumor effect in mice better than PD-1/PD-L1 monoab
Time of Update: 2020-07-12
Data presented by ChemoCentryx at the 2020 American Cancer Research Association (AACR) virtual meeting showed that the company's optimized oral checkpoint inhibitor CCX559 significantly inhibits PD-
-
Brukinsa, a BTK inhibitor in Baiji Shenzhou, is under review in Europe for the treatment of Fahrenheit polycyloproteinemia
Time of Update: 2020-07-12
Brukinsa (zanubrutinib, Zebtinib), a BTK small molecule inhibitor developed by Baiji Shenzhou, has been censored by European regulators to treat patients with Fahrenheit polycyteproteinemia (WM)
-
Blood: Arginine synthesis "buff" enhances the proliferation and anti-tumor efficacy of CAR-T cells
Time of Update: 2020-07-12
Blood and solid tumors break down the metabolism of the semi-essential amino acid arginine to drive cell proliferation, resulting in lower arginine levels in the tumor microenvironment The low argin
-
Blood: In multiple myeloma, monoclonal immunoglobulin promotes bone loss
Time of Update: 2020-07-12
Most patients with multiple myeloma develop severe bone-soluble diseases Myeloma cells secrete immune globulin, the presence of monoclonal immunoglobulin in the serum of patients is important dia
-
Blood: The Structural Foundation of PAR4 Activation and Its Role in VTE
Time of Update: 2020-07-12
Protease activation receptor 4 (PAR4) mediates the continuous signalconductofing of clotting enzymes in platelets, which is necessary to stabilize blood clots PAR4 is activated by protein hydrolys
-
Blood: RGS10 and RGS18 work together to limit unnecessary platelet activation
Time of Update: 2020-07-12
G protein conjugate receptor sishose activation is a key medium, and its signaling can be regulated by members of the G protein signal (RGS) family regulator The two most abundant RGS proteins in hu
-
Concerned about the rare disease "true red blood cell hypertrophy" :P TG-300 approved by FDA orphan drug
Time of Update: 2020-07-12
True erythropoietin (polycythemia vera, PV) is a bone marrow proliferation tumor, a group of malignant tumors derived from hematopoietic stem cells , characterized by the proliferation of bone marr
-
EU approves first red blood cell maturant Reblozyl to treat blood transfusion-dependent anemia
Time of Update: 2020-07-12
The European Commission has approved The BMS's Reblozyl (luspatercept) for the treatment of blood transfusion-dependent anemia associated with marrow hyperplasia syndrome (MDS) or beta thalassemia T
